141 results
8-K
EX-99.1
NAOV
NanoVibronix Inc
9 Apr 24
NanoVibronix Issues Letter to Stockholders
4:05pm
was not approved due to a lack of “life-cycle” testing. At that time, we engaged an independent testing laboratory, Carmel Labs, to conduct … in the study.
UroShield is marketed under the U.S. Food and Drug Administration’s (“FDA”) Enforcement Discretion, the intent of this independent study
8-K
5rr o1h3mws6rt7v09
11 Dec 23
Changes in Registrant's Certifying Accountant
4:30pm
8-K
EX-99.1
9lksmtr
28 Nov 23
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
9:00am
8-K
EX-99.1
6j0c12 j2
14 Nov 23
NanoVibronix Issues Letter to Shareholders
12:00am
424B3
c323i
21 Sep 23
Prospectus supplement
10:27am
8-K
ste31m17vmv fq
6 Sep 23
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
8:30am
8-K
EX-99.1
t7ljk 4jnyw8ypy7av
6 Sep 23
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
8:30am
8-K
EX-4.1
olf1pm
1 Sep 23
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:30pm